Earnings summaries and quarterly performance for Foghorn Therapeutics.
Executive leadership at Foghorn Therapeutics.
Adrian Gottschalk
Detailed
Chief Executive Officer
CEO
Alfonso Quintás-Cardama
Detailed
Chief Medical Officer
Anna Rivkin
Detailed
Chief Business Officer
Carlos Costa
Detailed
Chief People Officer
Kristian Humer
Detailed
Chief Financial Officer
Michael LaCascia
Detailed
Chief Legal Officer
Steven Bellon
Detailed
Chief Scientific Officer
Board of directors at Foghorn Therapeutics.
Research analysts covering Foghorn Therapeutics.
Recent press releases and 8-K filings for FHTX.
Foghorn Therapeutics Updates on Lilly Partnership and Pipeline Progress
FHTX
New Projects/Investments
Guidance Update
- Foghorn Therapeutics (FHTX) is a clinical-stage oncology company leveraging a drug discovery engine focused on chromatin biology to target historically undruggable proteins.
- Its primary program, the SMARCA2 inhibitor FHD-909, is part of a partnership with Eli Lilly, which included $300 million in upfront cash and $80 million in equity. This collaboration involves 50/50 cost-sharing and economics in the U.S. for the SMARCA2 program.
- Lilly is anticipated to make a decision on advancing FHD-909 into a dose expansion study in H1 2026. The company aims for a 15%+ response rate and 3+ months duration of therapy in the 3rd/4th line setting for SMARCA4 mutant cancers to consider it a success for expansion.
- Foghorn reported a cash position of $180 million at the end of Q3, which is projected to fund operations into early 2028, covering current program advancements.
Nov 19, 2025, 10:30 AM
Foghorn Therapeutics Provides Update on Clinical Programs and Financials
FHTX
New Projects/Investments
Guidance Update
- Foghorn Therapeutics provided an update on its clinical programs, highlighting its partnership with Eli Lilly for the SMARCA2 inhibitor FHD-909. The deal included $300 million upfront in cash and $80 million in equity at $20 per share, with Foghorn sharing 50% of costs and economics for the U.S. market.
- A decision from Lilly on proceeding to a dose expansion study for FHD-909 is anticipated in the first half of 2026. The drug is currently in a Phase I dose-escalation study for SMARCA4 mutant cancers.
- The company is also advancing proprietary programs, including selective CBP and EP300 degraders. The CBP degrader is expected to be IND ready by mid-2026, and the EP300 degrader is on track for IND-enabling studies towards the end of 2026.
- As of the end of Q3, Foghorn Therapeutics reported $180 million in cash on its balance sheet, providing a financial runway into early 2028.
Nov 19, 2025, 10:30 AM
Foghorn Therapeutics Provides Update on Clinical Programs and Financial Outlook
FHTX
New Projects/Investments
Guidance Update
- Foghorn Therapeutics (FHTX) is a clinical-stage oncology company focused on chromatin biology, with its main program, SMARCA2 inhibitor FHD-909, in partnership with Eli Lilly. The partnership involves a 50/50 cost-sharing and profit-sharing arrangement for SMARCA2 in the U.S., with royalties outside the U.S..
- The FHD-909 program is currently in a Phase 1 dose escalation study for SMARCA4 mutant cancers, and a decision on proceeding to a dose expansion study is expected in the first half of 2026.
- The company is advancing proprietary programs, including a CBP degrader aiming for IND readiness by mid-2026, an EP300 degrader targeting IND-enabling studies by late 2026, and an ARID1B program with a potential IND by late 2027.
- As of the end of Q3, Foghorn held $180 million in cash on its balance sheet, projected to fund operations into early 2028, covering the 909 program into dose expansion, a second Lilly target, and advancing proprietary programs to IND.
Nov 19, 2025, 10:30 AM
Foghorn Therapeutics Provides Update on Oncology Pipeline Development
FHTX
New Projects/Investments
Product Launch
- Foghorn Therapeutics is developing FHD-909, a SMARCA2 inhibitor, in collaboration with Lilly, targeting SMARCA4 loss of function cancers, with a focus on non-small cell lung cancer, representing an opportunity of 11,000-17,000 patients annually in the U.S..
- The Phase 1 study for FHD-909, which began in October 2024, has not yet reached its maximum tolerated dose, and a potential go-no-go decision for expansion is anticipated in the first half of 2026.
- The company's wholly-owned pipeline includes selective degraders for CBP and EP300, with the CBP program currently undergoing dose range finding studies and the EP300 program approximately 6-9 months behind.
- Foghorn is also advancing an ARID1B degrader, a target mutated in 5% of all solid tumors, with in vivo proof of concept expected in 2026.
Nov 10, 2025, 4:00 PM
Foghorn Therapeutics Provides Update on Pipeline Development and Financial Position
FHTX
New Projects/Investments
Guidance Update
- Foghorn Therapeutics has a strategic collaboration with Lilly, which included $380 million upfront and a 50/50 U.S. economic split on two lead programs, with potential milestones up to $1.3 billion.
- As of September 30, 2025, the company reported $180.3 million in cash and equivalents, providing a cash runway into 2028.
- The lead program, FHD-909 (Selective SMARCA2 Inhibitor), partnered with Lilly, is currently in a Phase 1 trial for SMARCA4 mutant cancers.
- Several preclinical assets, including Selective SMARCA2, CBP, EP300, and ARID1B Degraders, are advancing towards Investigational New Drug (IND) applications, with milestones such as IND-ready for Selective CBP Degrader and IND-enabling studies for Selective EP300 Degrader anticipated in 2026.
Nov 7, 2025, 9:33 PM
Foghorn Therapeutics Reports Q3 2025 Financials, Advances Pipeline, and Announces CFO Departure
FHTX
Earnings
CFO Change
New Projects/Investments
- Foghorn Therapeutics reported collaboration revenue of $8.2 million for the three months ended September 30, 2025, an increase from $7.8 million in the prior year period, and a net loss of $15.8 million, an improvement from a $19.1 million net loss in Q3 2024.
- The company holds a strong financial position with $180.3 million in cash, cash equivalents, and marketable securities as of September 30, 2025, extending its cash runway into 2028.
- The FHD-909 Phase 1 dose escalation trial for SMARCA4-mutated cancer remains on track.
- The Selective CBP degrader entered non-GLP toxicology studies in Q4 2025 and is anticipated to be IND-ready in 2026, while the Selective ARID1B degrader is advancing towards in vivo proof of concept in 2026.
- Kristian Humer, Chief Financial Officer, is departing the company on November 14, 2025, and a search for his successor has commenced.
Nov 5, 2025, 12:02 PM
Foghorn Therapeutics Updates Degrader Programs
FHTX
New Projects/Investments
Product Launch
- Foghorn Therapeutics announced updates on its Selective ARID1B, Selective CBP, and Selective EP300 degrader programs on October 30, 2025.
- The Selective ARID1B degrader is advancing towards in vivo proof of concept in 2026 and shows potential in up to 5% of all solid tumors.
- The Selective CBP degrader is on track for non-GLP toxicology studies in Q4 2025 and is expected to be IND-ready in 2026, with potential in EP300-mutant cancers and ER+ breast cancer.
- The Selective EP300 degrader demonstrates efficacy and favorable tolerability in preclinical models for hematological malignancies and is on track for IND-enabling studies in 2026.
Oct 30, 2025, 11:30 AM
Foghorn Therapeutics Announces Updates for Degrader Programs
FHTX
New Projects/Investments
- Foghorn Therapeutics provided updates on its Selective ARID1B, Selective CBP, and Selective EP300 degrader programs on October 30, 2025.
- The Selective ARID1B degrader program is advancing towards in vivo proof of concept in 2026, with data demonstrating selective degradation of ARID1B, potentially relevant in up to 5% of all solid tumors.
- The Selective CBP degrader is on track for non-GLP toxicology studies in Q4 2025 and is expected to be IND-ready in 2026, showing potential in EP300-mutant cancers and ER+ breast cancer.
- The Selective EP300 degrader program is on track for IND-enabling studies in 2026, demonstrating efficacy and favorable tolerability in preclinical models for hematological malignancies, with broad anti-tumor activity in over 70% of all heme sub-lineages tested.
Oct 30, 2025, 11:27 AM
Foghorn Therapeutics Inc. Publishes Q2 2025 Investor Presentation
FHTX
New Projects/Investments
Guidance Update
- Foghorn Therapeutics Inc. (FHTX) reported $198.7 million in cash and equivalents as of June 30, 2025, providing a cash runway into 2028.
- The company's strategic collaboration with Lilly, established in December 2021, included $380 million upfront and a 50/50 U.S. economic split on two lead programs, one of which is FHD-909.
- FHD-909, a Selective SMARCA2 Inhibitor, is currently in a Phase 1 monotherapy dose escalation trial, initiated by Lilly in 2024.
- Foghorn is also advancing multiple preclinical assets, such as Selective CBP Degrader and Selective EP300 Degrader, with IND/Phase 1 initiation planned for 2026.
Sep 2, 2025, 8:03 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more